The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Belimumab Promising for Children with Lupus Nephritis

Belimumab Promising for Children with Lupus Nephritis

October 6, 2022 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

In late July, the U.S. Food & Drug Administration (FDA) approved belimumab (Benlysta) for the treatment of children aged 5–17 years old with active lupus nephritis who are receiving standard therapy.1 Despite recent advances in treatment options for patients with systemic lupus erythematosus (SLE), those with kidney involvement face the possibility of developing end-stage renal disease and needing subsequent hemodialysis or transplantation. Belimumab may improve the prognosis for pediatric patients with lupus.

You Might Also Like
  • FDA Approves Belimumab & Voclosporin for Lupus Nephritis
  • Ixekizumab Promising for Non-Radiographic Axial SpA; Plus FDA Approves Belimumab for Pediatric Lupus
  • Monthly Belimumab Infusions Preserve Kidney Function in Some Lupus Patients
Explore This Issue
November 2022
Also By This Author
  • Drug Updates

The indications for the intravenous (IV) formulation of belimumab have been expanded to include pediatric patients with SLE, as well as those with active lupus nephritis.2 The recommended dosing of IV belimumab for pediatric patients is 10 mg/kg every two weeks for the first three doses, with subsequent infusions given at four-week intervals.3

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Background

The efficacy and safety of belimumab were evaluated for one year in a randomized, double-blind, placebo-controlled study (N=93; NCT01649765).4 Similar to the clinical trials of belimumab in adults, enrolled pediatric patients had to have a clinical diagnosis of SLE according to the ACR classification criteria, active SLE (i.e., defined as a SELENA-SLEDAI score of at least 6) and the presence of autoantibodies at screening.

The researchers enrolled 93 pediatric patients aged 5 to 17 years who were on stable treatment regimens for their SLE (i.e., standard therapy) and had similar inclusion and exclusion criteria as participants in the clinical trials for adults. The standard therapy included corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs) and/or immunosuppressives, alone or in combination. Use of other biologics and IV cyclophosphamide was not allowed during the course of this study.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The median patient age was 15 years (range: 6–17 years), and most patients were female (95%). At baseline, more than half of the patients had active involvement of at least three organ systems, the most common of which were the mucocutaneous (91%), immunologic (74%) and musculoskeletal (73%). Nineteen percent of patients had some degree of kidney disease, with less than 7% of patients having their cardio-respiratory, hematologic, central nervous system or vascular systems affected. The study’s primary efficacy end point was the SLE Responder Index (SRI-4) at week 52, as described in the adult trials of IV belimumab.

Results

Forty patients received placebo and standard therapy, and 53 patients received belimumab plus standard therapy. A higher proportion of patients receiving belimumab plus standard therapy achieved an SRI-4 response than patients who received placebo plus standard therapy (44% vs. 53%, odds ratio [OR]=1.49 (0.64, 3.46)).

Pages: 1 2 | Single Page

Filed Under: Conditions, Drug Updates, SLE (Lupus) Tagged With: belimumab, Children, FDA, FDA approval, kidney, Lupus nephritis, Pediatric, SLE Resource Center, U.S. Food and Drug Administration (FDA)Issue: November 2022

You Might Also Like:
  • FDA Approves Belimumab & Voclosporin for Lupus Nephritis
  • Ixekizumab Promising for Non-Radiographic Axial SpA; Plus FDA Approves Belimumab for Pediatric Lupus
  • Monthly Belimumab Infusions Preserve Kidney Function in Some Lupus Patients
  • The Great Debate: Belimumab vs. Voclosporin in Lupus Nephritis

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)